AU2008322858B2 - Quinoline derivatives and their use as tyrosine kinase inhibitors - Google Patents

Quinoline derivatives and their use as tyrosine kinase inhibitors Download PDF

Info

Publication number
AU2008322858B2
AU2008322858B2 AU2008322858A AU2008322858A AU2008322858B2 AU 2008322858 B2 AU2008322858 B2 AU 2008322858B2 AU 2008322858 A AU2008322858 A AU 2008322858A AU 2008322858 A AU2008322858 A AU 2008322858A AU 2008322858 B2 AU2008322858 B2 AU 2008322858B2
Authority
AU
Australia
Prior art keywords
compound according
substituted
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008322858A
Other languages
English (en)
Other versions
AU2008322858A1 (en
Inventor
Ulrika Backman
Johan Malm
Natalia Nekhotiaeva
Johan Wannberg
Jacob Westman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLANOTECH AB
Original Assignee
CLANOTECH AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLANOTECH AB filed Critical CLANOTECH AB
Publication of AU2008322858A1 publication Critical patent/AU2008322858A1/en
Application granted granted Critical
Publication of AU2008322858B2 publication Critical patent/AU2008322858B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008322858A 2007-11-15 2008-11-14 Quinoline derivatives and their use as tyrosine kinase inhibitors Active AU2008322858B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98814707P 2007-11-15 2007-11-15
US60/988,147 2007-11-15
EP07120799.7 2007-11-15
EP07120799 2007-11-15
PCT/EP2008/065596 WO2009063070A2 (fr) 2007-11-15 2008-11-14 Composés et procédés

Publications (2)

Publication Number Publication Date
AU2008322858A1 AU2008322858A1 (en) 2009-05-22
AU2008322858B2 true AU2008322858B2 (en) 2013-05-02

Family

ID=39295948

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008322858A Active AU2008322858B2 (en) 2007-11-15 2008-11-14 Quinoline derivatives and their use as tyrosine kinase inhibitors

Country Status (21)

Country Link
US (2) US8557843B2 (fr)
EP (1) EP2220047B1 (fr)
JP (1) JP5565841B2 (fr)
KR (1) KR101572929B1 (fr)
CN (1) CN103476755B (fr)
AU (1) AU2008322858B2 (fr)
BR (1) BRPI0820210A2 (fr)
CA (1) CA2705820C (fr)
DK (1) DK2220047T3 (fr)
EA (1) EA018798B1 (fr)
ES (1) ES2540219T3 (fr)
HR (1) HRP20150583T1 (fr)
HU (1) HUE025421T2 (fr)
IL (1) IL205308A (fr)
MX (1) MX2010005039A (fr)
NZ (1) NZ585090A (fr)
PL (1) PL2220047T3 (fr)
PT (1) PT2220047E (fr)
RS (1) RS54061B1 (fr)
SI (1) SI2220047T1 (fr)
WO (1) WO2009063070A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175079A (en) * 2010-04-02 2020-06-04 Firmenich Incorporated Sweet flavor modifier
MY179876A (en) 2011-08-12 2020-11-18 Firmenich Incorporated Sweet flavor modifier
US9376393B2 (en) * 2012-01-05 2016-06-28 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
MX2017005931A (es) 2014-11-07 2017-06-30 Senomyx Inc Acidos 4-amino-5- (ciclohexiloxi) quinolina-3-carboxilicos sustituidos como modificadores del sabor dulce.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO2008119771A2 (fr) * 2007-03-30 2008-10-09 Clanotech Ab Composés, utilisation et procédés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB0324270D0 (en) * 2003-10-16 2003-11-19 Univ Edinburgh Improved control of ES cell self-renewal and lineage specification, and medium therefor
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007139496A1 (fr) 2006-05-30 2007-12-06 Clanotech Ab Composés pouvant être employés en tant que médicament

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO2008119771A2 (fr) * 2007-03-30 2008-10-09 Clanotech Ab Composés, utilisation et procédés

Also Published As

Publication number Publication date
PL2220047T3 (pl) 2015-08-31
CA2705820A1 (fr) 2009-05-22
HRP20150583T1 (hr) 2015-07-31
WO2009063070A3 (fr) 2009-07-23
SI2220047T1 (sl) 2015-07-31
KR20100097158A (ko) 2010-09-02
US20110053976A1 (en) 2011-03-03
IL205308A0 (en) 2010-12-30
RS54061B1 (en) 2015-10-30
HUE025421T2 (en) 2016-02-29
EA201000803A1 (ru) 2011-02-28
US8957092B2 (en) 2015-02-17
WO2009063070A2 (fr) 2009-05-22
NZ585090A (en) 2011-09-30
CN103476755A (zh) 2013-12-25
AU2008322858A1 (en) 2009-05-22
KR101572929B1 (ko) 2015-11-30
EP2220047B1 (fr) 2015-05-06
DK2220047T3 (en) 2015-06-29
CN103476755B (zh) 2015-08-26
ES2540219T3 (es) 2015-07-09
PT2220047E (pt) 2015-07-30
JP2011503151A (ja) 2011-01-27
EP2220047A2 (fr) 2010-08-25
MX2010005039A (es) 2010-07-30
CA2705820C (fr) 2016-06-07
IL205308A (en) 2015-03-31
BRPI0820210A2 (pt) 2017-05-09
EA018798B1 (ru) 2013-10-30
US20140018388A1 (en) 2014-01-16
JP5565841B2 (ja) 2014-08-06
US8557843B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
AU2020281003B2 (en) Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
WO2010133672A1 (fr) Dérivés d'acide quinoléine-3-carboxylique et leur utilisation médicale
MX2013012190A (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
KR102426138B1 (ko) ＰＩ3Ｋ, ｍＴＯＲ 저해제로서 융합된 퀴놀린 화합물
US10053449B2 (en) Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
RU2266280C2 (ru) Замещенные производные n-бензилиндол-3-ил-глиоксиловой кислоты, обладающие противоопухолевым действием (варианты), их кислотно-аддитивные соли (варианты), фармацевтический препарат, фармацевтическая форма
US8957092B2 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
PT2609083E (pt) 2-oxi-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
US20120065199A1 (en) Substituted quinolines for use as vegf inhibitors
TWI681960B (zh) 苯并咪唑類衍生物及其製備方法及其在醫藥上的用途
US9840494B2 (en) Quinazoline derivative
UA102082C2 (uk) Похідні хіноліну та їх застосування як інгібіторів тирозинкінази
RU2562773C2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)